Korean Market
EXCH
Hanall Biopharma
★

Hanall Biopharma Loses ICC Arbitration Over Batoclimab License Termination with Harbor BioMed, Agreement Remains Valid

 
OWNR
Hanall Biopharma
★

National Pension Service Increases Stake in Hanall Biopharma from 10.05% to 10.84% - Steady Open Market Purchases by Major Institution

 
OWNR
Hanall Biopharma
★

National Pension Service Increases Stake in Hanall Biopharma to 10.56% for Passive Investment

 
EXCH
Hanall Biopharma
★

Hanall Biopharma Files 2025 Sustainability Report Voluntarily, No Direct Shareholder Value Impact from ESG Disclosures

 
EXCH
Hanall Biopharma
★

Hanall Biopharma Discloses Corporate Governance Report: No Dividends for 3 Consecutive Years, Continued Operating Loss, Long-Term Dividend Policy Established but Shareholder Returns Remain Uncertain

 
EXCH
Hanall Biopharma
★

Notice of Investor Relations Meeting… Schedule for Communication with Investors

 
EXCH
Hanall Biopharma
★

Conditional License Agreement for mRNA-based ERA Platform… Total $239M

 
EXCH
Hanall Biopharma
★★★★

Q1 2026 Operating Profit Swings to Black, Revenue Up 10.7%

 
MATR
Hanall Biopharma
★

Disposal of 66,004 Treasury Shares (0.13%) for Stock Option Exercise

 
PERI
Hanall Biopharma
★★

HanAll BioPharma Q1 Turns to Profit, Pipeline Advances; Harbour Arbitration Risk Remains

 
EXCH
Hanall Biopharma
★

HanAll Biopharma Major Shareholder Ownership Increases 0.04%

 
OWNR
Hanall Biopharma
★

No Change in Executive/Major Shareholder Holdings

 
OTHR
Hanall Biopharma
★

Hanall Biopharma Completes Disposal of 66,004 Treasury Shares

 
OWNR
Hanall Biopharma
★

Filing of Report on Ownership of Specific Securities by Executives and Major Shareholders (No Changes)

 
OWNR
Hanall Biopharma
★

No Material Changes in Executive/Major Shareholder Ownership Report